Generic Detrol LA Availability

See also: Generic Detrol

Detrol LA is a brand name of tolterodine, approved by the FDA in the following formulation(s):

DETROL LA (tolterodine tartrate - capsule, extended release; oral)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: December 22, 2000
    Strength(s): 2MG, 4MG [RLD]

Has a generic version of Detrol LA been approved?

No. There is currently no therapeutically equivalent version of Detrol LA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Detrol LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 3,3-diphenylpropylamines and pharmaceutical compositions thereof
    Patent 5,382,600
    Issued: January 17, 1995
    Inventor(s): Jonsson; Nils A. & Sparf; Bengt A. & Mikiver; Lembit & Moses; Pinchas & Nilvebrant; Lisbet & Glas; Gunilla
    Assignee(s): Pharmacia Aktiebolag
    ##STR1## Novel 3,3-diphenylpropylamines of formula (I) wherein R.sup.1 signifies hydrogen or methyl, R.sup.2, R.sup.3 and R.sup.4 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphanoyl or halogen, and X represents a tertiary amino group -NR.sup.5, R.sup.6, wherein R.sup.5 and R.sup.6 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and which may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers, their use as drugs, especially as anticholinergic agents, their use for preparing an anticholinergic drug, pharmaceutical compositions containing the novel amines, and methods for preparing the same.
    Patent expiration dates:
    • September 25, 2012
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical formulation and its use
    Patent 6,630,162
    Issued: October 7, 2003
    Inventor(s): Lisbeth; Nilvebrant & Bengt; Hallen & Birgitta; Olsson & Jan; Strombom & Torkek; Gren & Anders; Ringberg & Martin; Wikberg
    Assignee(s): Pharmacia AB
    The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
    Patent expiration dates:
    • November 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Drug product
    • May 11, 2020
      ✓ 
      Pediatric exclusivity
  • Therapeutic formulation for administering tolterodine with controlled release
    Patent 6,770,295
    Issued: August 3, 2004
    Inventor(s): Bo; Kreilgård & Lene; Orup Jacobsen & Ulla; Hoeck & Helle; Kristensen & Torkel; Gren & Lisbeth; Nilvebrant & Anders; Ringberg & Martin; Wikberg & Bengt; Hallén & Birgitta; Olsson & Jan; Strömbom
    Assignee(s): Pharmacia AB
    The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
    Patent expiration dates:
    • August 26, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Drug product
    • February 26, 2020
      ✓ 
      Pediatric exclusivity
  • Controlled release bead, a method of producing the same and multiple unit formulation comprising it
    Patent 6,911,217
    Issued: June 28, 2005
    Inventor(s): Gren; Torkel & Ringberg; Anders & Wikberg; Martin & Wald; Randy J.
    Assignee(s): Pharmacia AB
    A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.
    Patent expiration dates:
    • November 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Drug product
    • May 11, 2020
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
      ✓ 
      Pediatric exclusivity
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web2)